Expression of plasminogen activators and plasminogen activator inhibitor 1 in dedifferentiated chondrosarcoma

Cancer

Volumn 79, Issue 1, 1997, Pages 53-58

  Häckel, Carsten ^a   Czerniak, Bogdan ^b   Ayala, Alberto G ^b   Radig, Kathrin ^a   Roessner, Albert ^a  

^a OTTO VON GUERICKE UNIVERSITY   (Germany)

^b UNIVERSITY OF TEXAS   (United States)

Author keywords

dedifferentiated chondrosarcoma; plasminogen activator inhibitor 1 (PAI 1); tissue type plasminogen activator (t PA); urokinase type plasminogen activator (u PA)

Indexed keywords

PLASMINOGEN ACTIVATOR; PLASMINOGEN ACTIVATOR INHIBITOR 1; TISSUE PLASMINOGEN ACTIVATOR; UROKINASE;

ARTICLE; CHONDROSARCOMA; CLINICAL ARTICLE; HUMAN; HUMAN TISSUE; METASTASIS; PLASMINOGEN ACTIVATION; PRIORITY JOURNAL; PROTEIN INDUCTION; TUMOR GROWTH;

BONE NEOPLASMS; CHONDROSARCOMA; HUMANS; NEOPLASM PROTEINS; PLASMINOGEN ACTIVATOR INHIBITOR 1; PLASMINOGEN ACTIVATORS; SERINE PROTEINASE INHIBITORS; TISSUE PLASMINOGEN ACTIVATOR; URINARY PLASMINOGEN ACTIVATOR;

EID: 1842294627     PISSN: 0008543X     EISSN: None     Source Type: Journal    
DOI: 10.1002/(SICI)1097-0142(19970101)79:1<53::AID-CNCR8>3.0.CO;2-N     Document Type: Article

References (23)

1. Dahlin D, Beabot J. Dedifferentiation of low grade chondrosarcomas. Cancer 1971;28:461-6.
2. Campanacci M, Bertoni F, Capanna R. Dedifferentiated chondrosarcomas. Ital J Orthop Traumatol 1979;5:337-45.
3. Duffy MJ. The role of proteolytic enzymes in cancer invasion and metastasis. Clin Exp Metastasis 1992;10:145-55.
4. Quax PHA, vanMuijen GNP, Padersen N, deBart ACW, Schrauwen Y, Barlovatz-Meimon G, et al. The plasminogen activator system in extracellular matrix degradation. Fibrinolysis 1992;6:41-4.
5. Schmitt M, Jänicke F, Graeff H. Tumor-associated proteases. Fibrinolysis 1992;6:3-26.
6. Axelrod JH, Reich R, Miskin R. Expression of human recombinant plasminogen activators enhances invasion and experimental metastasis of H-ras transformed NIH 3T3 cells. Mol Cell Biol 1989;9:2133-41.
7. Ossowski L. In vivo invasion of modified chorioallantoic membrane by tumor cells: the role of cell surface-bound urokinase. J Cell Biol 1988;107:2437-45.
8. Ossowski L, Russo-Payne H, Wilson EL. Inhibition of urokinase-type plasminogen activator by antibodies: the effect on dissemination of a human tumor in the nude mouse. Cancer Res 1991;51:274-81.
9. Cajot JF, Schleuning WD, Medcalf RL, Bamat J, Testuz J, Liebermann L, et al. Mouse L-cells expressing human prourokinase-type plasminogen activator: effects on extracellular matrix degradation and invasion. J Cell Biol 1989; 109:915-25.
10. Quax PHA, van Muijen GNP, Weening-Verhoeff EJD, Lund LR, Dano K, Ruiter DJ, et al. Metastatic behavior of human melanoma cell lines in nude mice correlates with urokinase-type plasminogen activator, its type-1 inhibitor, and urokinase mediated matrix degradation. J Cell Biol 1991;115:191-9.
11. Häckel C, Radig K, Röse I, Roessner A. The urokinase plasminogen activator (u-PA) and its inhibitor (PAI-1) in embryo-fetal bone formation in the human: an immunohistochemical study. Anat Embryol (Berl) 1995;192:363-8.
12. Sumiyoshi K, Serizawa K, Urano T, Takada Y, Takada A, Baba S. Plasminogen activator system in human breast cancer. Int J Cancer 1992;50:345-8.
13. Sumiyoshi K, Baba S, Sakaguchi S, Urano T, Takada Y, Takada A. Increase in levels of plasminogen activator and type-1 plasminogen activator inhibitor in human breast cancer: possible roles in tumor progression and metastasis. Thromb Res 1991;63:59-71.
14. Reilly D, Christensen L, Duch M, Nolan N, Duffy MJ, Andreasen PA. Type-1 plasminogen activator inhibitor in human breast carcinomas. Int J Cancer 1992;50:208-14.
15. Sappino AP, Busso N, Belin D, Vassali JD. Increase of urokinase-type plasminogen activator in human lung and breast carcinomas. Cancer Res 1987;47:4043-6.
16. Heiss MM, Babic R, Allgayer H, Gruetzner KU, Jauch KW, Loehrs U, et al. Tumor-associated proteolysis and prognosis: new functional risk factors in gastric cancer defined by the urokinase-type plasminogen activator system. J Clin Oncol 1995;13:2084-93.
17. Hsu DW, Efird JT, Hedley-Whyte ET. Prognostic role of urokinase-type plasminogen activator in human gliomas. Am J Pathol 1995;147:114-23.
18. Häckel C, Ueda Y, Tsuchiya H, Herrera A, Blasius S, Roessner A. Plasminogen activators and their inhibitor in ostoesarcomas and other bone tumors. Zentralbl Pathol 1994;140:363-9.
19. Salonen EM, Vaheri A, Pöllänen J, Stephens R, Andreasen P, Mayer M, et al. Interaction of plasminogen activator inhibitor (PAI-1) with vitronectin. J Biol Chem 1989;264: 6339-43.
20. Sigurdardottir O, Wiman B. Studies on the interaction between plasminogen activator inhibitor-1 and vitronectin. Fibrinolysis 1992;6:27-32.
21. Vassalli JD, Baccino D, Belin D. A cellular binding site for the Mr 55,000 form of the human plasminogen activator, urokinase. J Biol Chem 1985;100:86-92.
22. Rabbani SA, Desjardins J, Bell AW, Banville D, Mazar A, Henkin J, et al. An amino-terminal fragment of urokinase isolated from a prostate cancer cell line (pc-3) is mitogenic for osteoblast-like cells. Biochem Biophys Res Commun 1990; 173:1058-64.
23. Simms WW, Ordonez NG, Johnston D, Ayala AG, Czerniak B. p53 expression in dedifferentiated chondrosarcoma. Cancer 1995;76:223-7.